Elizabeth Barrett is the Chief Executive Officer at UROGEN PHARMA LTD, a biopharmaceutical company focused on developing and commercializing innovative solutions for urothelial and specialty cancers. With an extensive background in the pharmaceutical and biotechnology industries, Barrett has played a pivotal role in steering UROGEN PHARMA LTD towards its mission of improving patient outcomes in underserved cancer markets. Prior to joining UROGEN PHARMA LTD, Barrett held several leadership positions at prominent organizations within the healthcare sector. Her career highlights include serving as the President and Chief Executive Officer at Foundation Medicine, where she successfully led the company through a period of significant growth and innovation in the field of cancer diagnostics. Barrett's strategic vision and operational expertise have been instrumental in driving the development and commercialization of novel therapies at UROGEN PHARMA LTD. Under her leadership, the company has made significant strides in advancing its pipeline of urology-focused treatments, with a particular emphasis on improving the quality of life for patients with rare and aggressive forms of cancer. As CEO, Elizabeth Barrett is responsible for overseeing the overall strategy and operations of UROGEN PHARMA LTD. Her commitment to fostering a culture of innovation and excellence has positioned the company as a leader in the development of targeted therapies for urothelial cancers. Barrett's leadership has been crucial in navigating the complex landscape of drug development and regulatory approval, ensuring that UROGEN PHARMA LTD remains at the forefront of delivering transformative treatments to patients in need.